Hepatitis B market getting heated

Published: 2012-12-12 06:56:00

Updated: 2012-12-12 06:56:00

Competition is about to heat up in the domestic anti-hepatitis drug market as Gilead Sciences’ Viread (tenofovir disoproxil fumarate), which has been launched here from Dec. 1, is expected to expanding its share of the domestic anti-hepatitis B market dominated by BMS’s Baraclude (entecavir).

The insurance price of Viread is set at 5,285 won per pill, which is lower than that of Baraclude.
...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.